Adalimumab biosimilar (Prestige BioPharma)
阿达木单抗生物类似药（Prestige BioPharma）
Report date: 2022/07/19 16:22:54
Base Information
Drug NameAdalimumab biosimilar (Prestige BioPharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A
Develop Information
Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A